Cortexyme expects Alzheimer's drug trial data by mid-Nov; shares hit record high

IRulya Therapeutics

09/08/2021 17:33

** Shares of biopharma co Cortexyme  CRTX.O  soar as much as
34% to touch a record high of $89.99 
    ** Stock among top five gainers on Nasdaq  .IXIC  
    ** CRTX says data from mid-to-late stage Alzheimer's drug
study expected by mid-November, earlier than previous
expectation of December 2021  urn:newsml:reuters.com:*:nBw8FFRBfa 
    ** CRTX expects current cash position of $153.5 mln to fund
operations through 2023 
    ** More than 620,000 shares traded, 3x its 25 DMA vol;
stock's busiest day since June 25
    ** Including session gains, stock up 207.7% YTD vs a fall of
50.5% in 2020

 (Reporting by Bhanvi Satija)
 ((Bhanvi.Satija@thomsonreuters.com;))